Optimization of direct oral anticoagulant prescribing in primary care: a pharmacotherapeutic review in real-world clinical practice and therapeutic efficiency
Abstract
Introduction Direct oral anticoagulants are among the first-line treatments for stroke prevention in patients with non-valvular atrial fibrillation and for the treatment and secondary prevention of venous thromboembolism. The increasing use of these agents poses challenges related to prescribing appropriateness, clinical safety. This study aims to evaluate the impact of a primary care pharmacist-led intervention on the appropriateness of DOAC prescribing, pharmacotherapeutic efficiency, and clinical outcomes. Materials and Methods A retrospective, quasi-experimental before-and-after study was conducted in the healthcare area of Xarxa Santa Tecla (Tarragonès and Baix Penedès, Spain). 791 patients receiving DOAC therapy were included. The intervention comprised multidisciplinary educational activities, individualized pharmacotherapeutic review, and communication of recommendations to prescribers. Results The mean age was 78.2 years, and 43.2% of patients had moderate or severe renal impairment. The pharmacotherapeutic review identified 527 patients (66.6%) as candidates for treatment optimization, through a proposed switch from apixaban to dabigatran. The pharmacist intervention was associated with changes in prescribing patterns among newly initiated patients, increasing the use of dabigatran. The economic analysis estimated savings of €75,508.81 from new treatment initiations and €31,288.25 from therapeutic switches, resulting in total savings of €106,797.06 in 2025. The overall bleeding rate remained stable (5.3% in 2024% vs. 5.2% in 2025), with no deterioration in clinical safety. In conclusion, a structured, multidisciplinary, and coordinated primary care pharmacist-led intervention promoted a more efficient use of healthcare resources, while no deterioration in population-level safety indicators was observed. These findings reinforce the role of primary care pharmacists in optimizing anticoagulant therapy.